iBioPharma, Inc.’s Pandemic Flu Vaccine Effective in Ferret Model

NEWARK, Del.--(BUSINESS WIRE)--iBioPharma, Inc. (OTCBB:IBPM) today announced positive results from preclinical immunogenicity and efficacy studies of the Company’s H5N1 subunit vaccine candidates. The studies were performed in ferrets, which are the preferred animal model for testing the efficacy of candidate influenza vaccines prior to human clinical trials. “We are revising the Company’s previous forecast by giving a higher priority to clinical development of our pandemic flu vaccine candidates,” said Robert B. Kay, Chairman and CEO of iBioPharma.